Stinger

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

Retrieved on: 
Thursday, August 25, 2022
COVID-19, Safety, Research, Scratching, Duane syndrome, Insurance, Risk, Science, Dry eye syndrome, U.S. Securities and Exchange Commission, Jumpstart Our Business Startups Act, Antibody, GLOBE, Company, Rest, User experience, Patient, Lipid, NK, Protein, Nose, INT, Nasdaq, FDA, Throat irritation, Woman, Oyster Point, Trigeminal nerve, IgG4-related ophthalmic disease, Security (finance), Stinger, LinkedIn, Homeostasis, Patent, MD, Menopause, Autoimmune disease, Parasympathetic nervous system, Sneeze, Private Securities Litigation Reform Act, Cough, Nach, Treatment, Pharmacy, Tax Cuts and Jobs Act of 2017, Prevalence, Eye, Pharmaceutical industry, Signs and symptoms, Varenicline, Ophthalmology

We look forward to this years WIO Summer Symposium, a curated meeting for women offering content in all subjects of importance to women ophthalmologists, said Marian Macsai, MD chief medical officer, Oyster Point Pharma.

Key Points: 
  • We look forward to this years WIO Summer Symposium, a curated meeting for women offering content in all subjects of importance to women ophthalmologists, said Marian Macsai, MD chief medical officer, Oyster Point Pharma.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.
  • Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.

Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cream, People, Inflammatory bowel disease, Inflammation, Pain, Obesity, Research, Smoking, Regulation of tobacco by the U.S. Food and Drug Administration, Genetics, Swelling, Psoriasis Area and Severity Index, Nose, Calendar, Aryl hydrocarbon receptor, Psoriasis, Rash, Stinger, Common, Incidence, Risk, Itch, Irritation, Food, Body surface area, Skin, LinkedIn, Roivant Sciences, Dermatology Life Quality Index, Headache, Quality of life, Cell, Depression, Itchy, Journal of the European Academy of Dermatology and Venereology, Hypertension, FDA, Therapy, Atopic dermatitis, Pivotal, Weather, Efficiency, Diabetes, Congress, Gesellschaft mit beschränkter Haftung, Folliculitis, Marketing, Patient, Cosmetics, Pharmaceutical industry, Venereology, Dermatology

VTAMA cream is approved for mild, moderate and severe plaque psoriasis, with no label restrictions on duration of use or body surface area.

Key Points: 
  • VTAMA cream is approved for mild, moderate and severe plaque psoriasis, with no label restrictions on duration of use or body surface area.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.
  • The FDA approved VTAMA cream for the topical treatment of mild, moderate, and severe plaque psoriasis in May 2022.

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

Retrieved on: 
Wednesday, August 17, 2022
FDA, User experience, Trigeminal nerve, Cough, Antibody, Safety, U.S. Securities and Exchange Commission, Tax Cuts and Jobs Act of 2017, Sneeze, Medicare, GLOBE, Throat irritation, Private Securities Litigation Reform Act, MMS, NK, Prescription, Prevalence, Dry eye syndrome, Patent, Security (finance), INT, Research, Patient, IgG4-related ophthalmic disease, COVID-19, Doctor of Philosophy, Company, Rest, Lipid, Medicare Part D, Nose, Eye, Signs and symptoms, Nasal spray, Duane syndrome, Ophthalmology, Pharmacy, Scratching, Nach, Risk, Â, Homeostasis, Stinger, Science, Protein, Insurance, Nasdaq, LinkedIn, Parasympathetic nervous system, Jumpstart Our Business Startups Act, Pharmaceutical industry, Varenicline

We are committed to growing patient access and are looking forward to continue engaging with Medicare Part D health plans.

Key Points: 
  • We are committed to growing patient access and are looking forward to continue engaging with Medicare Part D health plans.
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point Pharma has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.

Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022

Retrieved on: 
Monday, August 15, 2022
FDA, Antibody, User experience, Trigeminal nerve, Cough, Safety, U.S. Securities and Exchange Commission, Tax Cuts and Jobs Act of 2017, Sneeze, GLOBE, Throat irritation, Private Securities Litigation Reform Act, MMS, NK, Prevalence, Dry eye syndrome, Patent, Security (finance), INT, Research, Patient, IgG4-related ophthalmic disease, COVID-19, Company, Rest, Lipid, Nose, Eye, Signs and symptoms, Nasal spray, Duane syndrome, Ophthalmology, Pharmacy, Scratching, Nach, Risk, Homeostasis, Stinger, Science, Protein, Insurance, Nasdaq, LinkedIn, Conference, Parasympathetic nervous system, Jumpstart Our Business Startups Act, Pharmaceutical industry, Varenicline

PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (Oyster Point Pharma, or the Company), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Dr. Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Oyster Point Pharma, will attend the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place on Wednesday, August 17, 2022.

Key Points: 
  • PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (Oyster Point Pharma, or the Company), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Dr. Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Oyster Point Pharma, will attend the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place on Wednesday, August 17, 2022.
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point Pharma has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.

Bug Bite Thing Announces New Retail Partners in 2022, Including Dunham's Sports, Meijer, Rite Aid, and Walgreens and Continues Global Expansion

Retrieved on: 
Tuesday, August 9, 2022
Boy, Rite Aid, ABC, Insect bites and stings, Sport, Sting, Scouting in Florida, Amazon (company), Saliva, Dunham's Sports, Commerce, Shark Tank, Golden Ticket, Itch, Instagram, Twitter, TikTok, Business Center, Suction, Partnership, Skin, Biting, Shark, National Parents Organization, Stinger, Amazon, PORT, LinkedIn, Swelling, Beekeeping, Walgreens, Facebook, Meijer

PORT ST. LUCIE, Fla., Aug. 9, 2022 /PRNewswire/ -- Bug Bite Thing , the chemical-free, reusable insect bite relief suction tool, is thrilled to announce new retail partners, including Dunham's Sports, Meijer, Rite Aid, and Walgreens.

Key Points: 
  • PORT ST. LUCIE, Fla., Aug. 9, 2022 /PRNewswire/ -- Bug Bite Thing , the chemical-free, reusable insect bite relief suction tool, is thrilled to announce new retail partners, including Dunham's Sports, Meijer, Rite Aid, and Walgreens.
  • Bug Bite Thing is now available in stores in the following locations:
    Dunham's Sports in the Midwest, Northeast, Mid-Atlantic and Southeast regions.
  • "It has been an incredible experience to walk into stores and see Bug Bite Thing on the shelves.
  • Learn more at Bug Bite Thing , and follow along on Facebook , Instagram , LinkedIn , TikTok , and Twitter .

Dr. Jennifer Shaba Promotes July's Dry Eye Awareness Month Through Education

Retrieved on: 
Wednesday, July 27, 2022
People, Publishing, Knowledge, Environment, Eye, Awareness, Herbal cigarette, Blood, Wind, Duane syndrome, Woman, Visual impairment, Dry eye syndrome, Tablet, Intense, Menopause, Smoke, Health, Red, Computer, Rosacea, Pregnancy, Quality of life, MGD, Inflammation, Itch, Technology, Ageing, WEST, Patient, Mucus, IPL, Androgen deficiency, Light, Efficiency, Stinger, Exocrine gland, Intense pulsed light, Blinking, Tears, Cosmetics, Blepharitis

WEST BLOOMFIELD, Mich., July 27, 2022 /PRNewswire-PRWeb/ -- 16 million people suffer from dry eye (Source: Prevent Blindness) but they don't always know the causes, symptoms, or cure. Dr. Jennifer Shaba of Dry Eye Healing Institute is spending July raising awareness of what dry eye is, how it happens and what people can do to treat dry eye. Dr. Shaba is publishing content, speaking to groups, and distributing materials to address misconceptions about dry eye.

Key Points: 
  • Dr. Jennifer Shaba of Dry Eye Healing Institute is spending July raising awareness of what dry eye is, how it happens and what people can do to treat dry eye.
  • Dr. Jennifer Shaba of Dry Eye Healing Institute is spending July raising awareness of what dry eye is, how it happens and what people can do to treat dry eye.
  • Dr. Shaba is publishing content, speaking to groups, and distributing materials to address misconceptions about dry eye.
  • Dry Eye Healing Institute takes a novel approach to dry eye by mitigating both the signs and symptoms of Dry Eye Disease and Blepharitis.

Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®

Retrieved on: 
Wednesday, July 27, 2022
Date, Prescription, Lipid, MMS, Safety, Scratching, Company, Security (finance), LinkedIn, Doctor of Philosophy, Parasympathetic nervous system, IgG4-related ophthalmic disease, Eye, Protein, U.S. Securities and Exchange Commission, Research, Medicare Part D, Trigeminal nerve, Throat irritation, Stinger, Rest, User experience, Prevalence, Nose, Antibody, Nasal spray, GLOBE, Insurance, Nach, Risk, Patent, COVID-19, ECP, Duane syndrome, Jumpstart Our Business Startups Act, FDA, Science, Nasdaq, Sneeze, Medicare, INT, Ophthalmology, Cough, Dry eye syndrome, Pharmacy, Private Securities Litigation Reform Act, Signs and symptoms, Office of Commercial Space Transportation, Patient, Tax Cuts and Jobs Act of 2017, NK, Homeostasis, Pharmaceutical industry, Health insurance, Varenicline

The Company has also introduced in July expanded patient access programs to include more eligible patients.

Key Points: 
  • The Company has also introduced in July expanded patient access programs to include more eligible patients.
  • The expansion of patient access to TYRVAYA comes as the Company continues to build upon its launch success.
  • Our newly expanded patient access program aligns with our commitment to optimize access to TYRVAYA for as many eligible patients as possible.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Folliculitis, Swelling, Rash, Itch, Atopic dermatitis, Research, CEO, CRO, Headache, Incidence, Skin, Partnership, Data analysis, Scaly, Quality of life, Medical Affairs Bureau, Itchy, Biotechnology, FDA, Roivant Sciences, Patient, LinkedIn, Psoriasis, The New England Journal of Medicine, Pain, Therapy, Efficiency, Stinger, Irritation, Common, Nose, Pharmaceutical industry, Medical device

Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis.

Key Points: 
  • Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis.
  • Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults.
  • Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials.

VTAMA® (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD

Retrieved on: 
Tuesday, June 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Cream, People, Efficiency, Acne, FDA, Patient, LTE, Vitiligo, LinkedIn, Journal, Adult, Nose, Research, American Academy, PGA, Itch, Common, Atopic dermatitis, Pain, Depression, Global Assessment of Functioning, Obesity, Risk, Therapy, Headache, Stinger, Psoriasis, Roivant Sciences, Folliculitis, Quality of life, Irritation, Rash, JD, Skin, Inflammatory bowel disease, Incidence, Hypertension, Swelling, Safety, Upper respiratory tract infection, Body surface area, Diabetes, Pharmaceutical industry, Cosmetics, MD, JAAD

VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.

Key Points: 
  • VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.
  • Newly published final data in JAAD includes efficacy outcomes, quality of life, safety, and tolerability assessments observed over long-term use of VTAMA (tapinarof) Cream, 1%.
  • The PSOARING 3 LTE study forms part of Dermavants pivotal Phase 3 plaque psoriasis clinical program for VTAMA Cream.
  • On May 24, Dermavant announced that the FDA had approved VTAMA (tapinarof) Cream, 1% for the treatment of adult plaque psoriasis.

Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®

Retrieved on: 
Wednesday, June 15, 2022
Oyster Point, Security (finance), Science, Throat irritation, American Optometric Association, LinkedIn, Lipid, Protein, MD, Dry eye syndrome, GLOBE, Prevalence, Cough, Patent, Risk, Stinger, Tax Cuts and Jobs Act of 2017, Signs and symptoms, Private Securities Litigation Reform Act, Duane syndrome, IgG4-related ophthalmic disease, INT, Nasdaq, Jumpstart Our Business Startups Act, Sneeze, FDA, COVID-19, Trigeminal nerve, Pharmacy, User experience, Adult, Patient, U.S. Securities and Exchange Commission, Antibody, Nach, NK, Eye, Safety, Scratching, Company, Ophthalmology, Student, Research, Nose, Parasympathetic nervous system, Rest, Homeostasis, Pharmaceutical industry, Optometry, Varenicline

Oyster Point is honored to be recognized at this years Optometry's Meeting with a distinction that is reserved for the years top five scientific abstracts, among nearly two hundred submissions, said Marian Macsai, MD, chief medical officer, Oyster Point Pharma.

Key Points: 
  • Oyster Point is honored to be recognized at this years Optometry's Meeting with a distinction that is reserved for the years top five scientific abstracts, among nearly two hundred submissions, said Marian Macsai, MD, chief medical officer, Oyster Point Pharma.
  • In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.
  • Optometry's Meeting is a registered trademark of the American Optometric Association.